KALV
KalVista Pharmaceuticals, Inc. · Healthcare
20.25
0.30%(+0.06)
Market OpenLast Updated: — ET
52W L: $9.2352W H: $21.30
$20.14
CHG+4.50 (+28.77%)
H$21.31
L$15.00
VOL19M
KALV (1h)
KalVista Pharmaceuticals, Inc. · Healthcare
KalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind. Looking ahead, Ekterly's potential pediatric expansion into ages 2 to 11 could add meaningful upside.
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista's Board of Directors granted five newly-hired employees inducement options to purchase an aggregate of 66,375 shares of KalVista common stock on April 1, 2026 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock.
FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new interim results from its KONFIDENT-KID clinical trial evaluating EKTERLY® (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children ages 2-11 presented at the 2026 Global Angioedema Leadership Conference. KONFIDENT-KID is the largest pediatric trial ever conducted in HAE. It features a proprietary oral disintegrating tablet (ODT) formulat.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report) shot up 8.7% on Thursday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $18.82 and last traded at $18.6350. 837,871 shares traded hands
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday after Stifel Nicolaus raised their price target on the stock from $39.00 to $42.00. Stifel Nicolaus currently has a buy rating on the stock. KalVista Pharmaceuticals traded as high as $19.27 and last traded at
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
Venrock Healthcare Capital Partners III, L.P.
10 percent owner
174,485 SH @ $16.95
2026-03-25
Venrock Healthcare Capital Partners III, L.P.
10 percent owner
160 SH @ $17.53
2026-03-25
Venrock Healthcare Capital Partners III, L.P.
10 percent owner
21,386 SH @ $17.76
2026-03-26
Venrock Healthcare Capital Partners III, L.P.
10 percent owner
15,417 SH @ $18.82
2026-03-26
Venrock Healthcare Capital Partners III, L.P.
10 percent owner
3,183 SH @ $19.12
2026-03-26
Palleiko Benjamin L
director, officer: CHIEF EXECUTIVE OFFICER
15,625 SH @ $0.00
2026-03-06
Palleiko Benjamin L
director, officer: CHIEF EXECUTIVE OFFICER
6,693 SH @ $16.08
2026-03-09
Palleiko Benjamin L
director, officer: CHIEF EXECUTIVE OFFICER
15,625 SH @ $0.00
2026-03-06